about
Which patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majorityDirect oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes.Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry.Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.Capsule Commentary on Al-Khatib et al., Future Research Prioritization: Implantable Cardioverter Defibrillator Therapy in Older Patients.Nebivolol for the treatment of heart failure.Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature.Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants.Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis.Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism.Risk of recurrence of unusual site venous thromboembolism.Clinical manifestations and imaging tools in the diagnosis of splanchnic and cerebral vein thromboses.Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients.Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry.Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis.Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry.Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study.Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: a multicenter retrospective cohort study.Incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio.Pulmonary embolism severity index accurately predicts long-term mortality rate in patients hospitalized for acute pulmonary embolism.Prevalence of renal failure and use of antithrombotic prophylaxis among medical inpatients at increased risk of venous thromboembolic events.A comparative study using thrombin generation and three different INR methods in patients on Vitamin K antagonist treatment.Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study.Age-adjusted D-dimer to rule out deep vein thrombosis: findings from the PALLADIO algorithm.Benefits and challenges of going abroad for research or clinical training.Treatment of acute migraine attacks in children with analgesics on the World Health Organization Essential Medicines List: A systematic review and GRADE evidence synthesis.Multiple overlapping systematic reviews facilitate the origin of disputes: the case of thrombolytic therapy for pulmonary embolism.TB-402 for the prevention of venous thromboembolism in orthopaedic surgery: something new and promising, or not?Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study.Anticoagulant therapy in atrial fibrillation: vitamin K antagonists or novel oral anticoagulant drugs?Safety and efficacy of low-dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR studyBiomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectinEstimating renal function in patients with atrial fibrillation: which dose of direct oral anticoagulants?Oral antithrombotic therapy and gastrointestinal bleeding: the good, the bad and the uglyAdvancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillationUnmet clinical needs in the management of patients with splanchnic vein thrombosisAccuracy of age-adjusted D-dimer to rule out deep vein thrombosis in the elderlySplanchnic Vein Thrombosis: Current PerspectivesValidation and psychometric properties of the Maltese version of the Duke Anticoagulation Satisfaction Scale (DASS)Reliability and validity of the Maltese version of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q)
P50
Q26849407-1EBF99F0-8D48-4DC1-93AC-80DDBB630A85Q30979197-F9522E6B-948A-45D6-905F-09B2AAB15161Q33412386-703E4778-0FD6-42D8-AF38-210AC41BB029Q35569714-E9012AC3-C7F1-41DB-B9B7-6789783870DFQ36258397-D125B348-2DFA-499A-BC2F-D9B82F4177E3Q37943377-58367880-BEDE-460B-A7AC-512F27370560Q38052502-E3BE724D-C6C3-4C13-BD5F-77E7B7EDAF70Q38363775-9E78EC00-85FB-459D-81F4-DE21CCA75FF2Q38691974-986B6EC9-8935-46E1-B3B0-18D31416DAFFQ38956538-A9E28C9E-F799-40C4-9C99-C25427973889Q39404102-9BD50518-CB6B-463F-BBEC-B1385845F4CAQ39412079-7C7D4596-D97C-4037-9C35-9B5EA548C711Q39452848-61883480-72A2-4797-8CDD-E87FA400A2BAQ39708703-E1251F1E-800D-4FAE-A0C5-5C953A21ED3FQ39875334-04E9BCD9-024C-45C7-88FB-E39D2DE5DBFDQ40744463-BA77A319-5EFD-42EE-AFA1-C5616CFCB62BQ42142659-CC9EFD1B-CC74-445A-923E-DDDF647FBB93Q42399860-9E06E6E8-5152-42E8-AB85-BBAF9C43E80FQ44356219-F6E0AAD5-72EA-4938-A121-F479E98B2A4BQ44396662-3ED4D1C6-45F0-47F1-B0EE-F1B533024EFEQ45156380-8F96BD1C-93A6-4CCA-8170-1BC61884487EQ45867663-E7C6563C-D327-4B0D-BA66-3D2AD97BE6D4Q45874680-60FAB13F-C0A4-4CE8-BF17-22E51F483C45Q47612787-4AD5B164-AF05-41D9-9DE2-4E53D6A20113Q47612796-3F4766AD-E9F8-4AE9-9738-42D2DA12EC8BQ47653670-29780629-18FF-422A-B916-EF950C5308E6Q49633022-CD9FCFDF-9C2C-415B-B901-C185B47B2BA4Q50991512-ABB53332-7A65-4140-8B9E-612916A98F12Q51136071-A49E747E-38E4-4010-A232-C930B0DA6943Q51758040-4C905E6D-C2F3-48E5-B899-A6FFB4A30A8FQ58420854-9DE8CF3A-3510-4472-AFDD-883E1A73AF06Q63242296-AA122A9A-9AAE-45BB-B816-647D9C2B2042Q63242297-46DF9C28-C0F5-4490-9A67-B16BE951EF04Q63242346-E41FE9AA-F730-4D1B-9071-2501699AA272Q63242348-D6CA97ED-4279-44E2-A5D1-92419C93543EQ63242349-9D8B5A2B-1F3B-48E5-BB15-943D307C0980Q91004451-FFB24EC3-4991-463C-A079-EF7DC50060ADQ91153006-DAD6C3E3-45FD-4904-877E-961F98F8F0C3Q91153592-2F2C6E08-A3AA-458B-845A-0E4A476D5282Q92648494-89CB2184-B612-4B64-9C8F-A8938357B1AF
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nicoletta Riva
@ast
Nicoletta Riva
@en
Nicoletta Riva
@es
Nicoletta Riva
@nl
Nicoletta Riva
@sl
type
label
Nicoletta Riva
@ast
Nicoletta Riva
@en
Nicoletta Riva
@es
Nicoletta Riva
@nl
Nicoletta Riva
@sl
prefLabel
Nicoletta Riva
@ast
Nicoletta Riva
@en
Nicoletta Riva
@es
Nicoletta Riva
@nl
Nicoletta Riva
@sl
P106
P1153
24512606100
P21
P31
P496
0000-0002-8922-8823